
Please try another search
By Liz Moyer
Investing.com -- Amgen (AMGN) reported third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
The biotech company reported earnings per share of $4.70 on revenue of $6.7 billion. Analysts anticipated EPS of $4.45 on revenue of $6.58 billion.
Amgen shares rose 1% in after-hours trading. They are up 18% from the beginning of the year, but down 3.27% from a 52-week high of $274.88 set on Nov. 2.
Revenue for the quarter was up 1% on growth from its treatments for cancer, rheumatology and heart products helped blunt the effects of lower prices and foreign exchange challenges.
For the full year, Amgen is forecasting a narrower range for adjusted EPS of $17.25 to $17.85 and revenue in a range of $26 billion to $26.3 billion. It earlier forecast an EPS range of $17 to $18 on revenue of $25.5 billion to $26.4 billion.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.